Atherotech To Exhibit VAP(R) Cholesterol Test At American Heart Association Scientific Sessions 2008

Main Category: Cholesterol
Also Included In: Conferences
Article Date: 07 Nov 2008 - 0:00 PST

email to a friend   printer friendly   opinions  

Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans.

Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No. 2918, and the VAP Test will be provided via blood draw to qualified attendees. Test results will be returned via mail after the conference.

The VAP (vertical auto profile) Test is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.

"Detailed risk profiling through advanced lipid testing is changing the way we evaluate and manage heart disease risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is affordable, widely covered by insurance and will play an increasingly important role in heart attack and stroke prevention."

The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL ratio.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test.

The VAP Cholesterol Test has been shown to identify significantly more patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). Risks of both heart disease and diabetes can be reduced with the right preventive treatments, which is why more accurate diagnosis is critical.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's patented VAP(R) technology, which directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for LDL measurement and the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Cholesterol Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.

Atherotech, Inc.
http://www.atherotech.com

• Additional
• References
• Citations